Ceraxon, 500 mg/4 ml 4 ml 5 pcs

Ceraxone is a nootropic drug.

Cyticolin, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes the repair of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission.

In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, moreover, citicoline helps to reduce the duration of recovery period.

In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Ceraxone^® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

Active ingredient

Composition

4 ml solution contains:

the active ingredient:

citicoline sodium (equivalent to 500 mg of citicoline)

excipients:

1M hydrochloric acid or 1M sodium hydroxide to pH 6.7-7.1;

water for injection to 4 ml

How to take, the dosage

The drug is administered intravenously as a slow injection (over 3-5 minutes, depending on the prescribed dose) or as a drip infusion (40-60 drops per minute). Intravenous route of administration is preferable to intramuscular route. When administering intramuscularly, repeated administration of the drug at the same site should be avoided.

Acute period of ischemic stroke and craniocerebral injury: Recommended dose is 1000 mg every 12 hours from the first day of diagnosis; treatment duration is at least 6 weeks. After 3-5 days of treatment (if swallowing function is not impaired), conversion to oral forms of Zeraxone® is possible.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of craniocerebral trauma, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day. (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Interaction

Citicoline enhances the effects of levodopa.

Ceraxone® should not be administered simultaneously with drugs containing meclofenoxate.

Special Instructions

During treatment, caution should be exercised when performing potentially hazardous activities requiring special attention and quick reactions (driving a car and other vehicles, working with moving machinery, work of a dispatcher and operator, etc.).

The oral solution (optional). Slight amounts of crystals may form in the cold due to temporary partial crystallization of the preservative. The crystals will dissolve within a few months if stored under the recommended conditions. The presence of crystals does not affect the quality of the product.

Contraindications

Side effects

Very rare (less than 1/10000) (including individual cases): allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in liver enzyme activity. In some cases, Zeraxone® may stimulate the parasympathetic system and also cause short-term changes in BP.

If any of the side effects listed in the instructions worsen, or if any other side effects not listed in the instructions are noticed, you should tell your doctor.

Overdose

In view of the low toxicity of the drug, no cases of overdose have been described.

Pregnancy use

There are no sufficient data on the use of citicoline in pregnant women. Although no adverse effects have been shown in animal studies, during pregnancy the drug Zeraxone® is prescribed only when the expected benefit to the mother exceeds the potential risk to the fetus.

When prescribing Ceraxon® during lactation women should stop breastfeeding because there is no data on excretion of citicoline with the woman’s milk.

Similarities